Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-357 vs Ticagrelor in Healthy Volunteers
NCT03671941Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- May 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-357 in acute coronary syndrome (ACS) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last measurable concentration (AUCt) of Ticagrelor at 48 hours and Maximum Plasma Concentration (Cmax) of Ticagrelor at 48 hours. Started May 2018; status: completed.
02
Drugs
CKD-357
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT03671941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03671941.